Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Growth Metrics
Income Statement
Others
Ratios

Gsk (GLAXF) Accounts Payables (2016 - 2025)

Gsk has reported Accounts Payables over the past 10 years, most recently at $20.5 billion for Q4 2025.

  • Quarterly results put Accounts Payables at $20.5 billion for Q4 2025, up 3.95% from a year ago — trailing twelve months through Dec 2025 was $20.5 billion (up 3.95% YoY), and the annual figure for FY2025 was $20.5 billion, up 3.95%.
  • Accounts Payables for Q4 2025 was $20.5 billion at Gsk, up from $19.7 billion in the prior quarter.
  • Over the last five years, Accounts Payables for GLAXF hit a ceiling of $23.7 billion in Q4 2021 and a floor of $19.1 billion in Q4 2022.
  • Median Accounts Payables over the past 5 years was $19.7 billion (2024), compared with a mean of $20.5 billion.
  • Biggest five-year swings in Accounts Payables: rose 13.13% in 2021 and later dropped 19.39% in 2022.
  • Gsk's Accounts Payables stood at $23.7 billion in 2021, then decreased by 19.39% to $19.1 billion in 2022, then increased by 3.09% to $19.7 billion in 2023, then increased by 0.09% to $19.7 billion in 2024, then rose by 3.95% to $20.5 billion in 2025.
  • The last three reported values for Accounts Payables were $20.5 billion (Q4 2025), $19.7 billion (Q4 2024), and $19.7 billion (Q4 2023) per Business Quant data.